Forum Agenda

July 24,09:00-12:00

China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies

Stay tuned

Planner/Meeting Hosts

Keiji Kawamoto:Representative, Kawamoto BioBusiness Partners / Senior Advisor, Shanghai Deband Law Firm

Ruiping Dong:Founder and Chairman, RealOne Medicines

 

09:00-09:05 Opening Remarks
Zhengqian Niu: Chairman, Internationalization Committee, China Pharmaceutical Enterprises Association (CPEA)

 

09:05-09:30 Latest Trends and Innovation Environment in Japan's New Drug Market
Yuji Kato: Editor in Chief, Nikkei Biotechnology & Business, Nikkei Business Publications, Inc.

 

09:30-09:55 How Does Japan Join a China-Dominant Clinical Trial to Get Approval by PMDA?
Fugen Li: SVP, Haihe Biopharma

 

09:55-10:20 Practical Guidance for Initiating Clinical R&D of Chinese Innovative Drugs in Japan
Toshimi Nouchi: Executive Officer, Global Business Promotion, EPS Corporation

 

10:20-10:45 MNC Reverse Roadshow
Kazunari Tsukamoto: SVP and Global Head of BD, Astellas

 

10:45-11:10 Collaborative Synergy with Japanese R&D Institutions and Biopharma Enterprises
Hiroki Narita: CEO, Daiwa Corporate Investment (DCI)

 

11:10-12:00 Panel Discussion: Global Footprint Strategy for Chinese Innovative Drugs — How to Leverage Japan's Market to Boost Overseas Expansion Strategies
Ruiping Dong(Moderator):Founder and Chairman, RealOne Medicines

Yoshiaki Maruyama:Director, Regulatory Review Department for Regenerative Medical Products, PMDA, Japan

Tetsuya Hagiwara:Vice President, Head of BD, Japan, Kyowa Kirin

Jianghu Piao:General Manager, International BD, Corporate Strategy, Toho Holding Co., Ltd.; Chairman, Hubei Gongchuang Pharmaceutical

Anbo Xiang:CMO of Non-Oncology, CSPC Pharmaceutical Group

Xiao Han:Director, Tigermed